Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial stage biopharmaceutical company focused on developing innovative cancer therapies, has announced the granting of an inducement award under its 2023 Inducement Plan. On September 1, 2024, the company granted stock options to purchase up to 60,000 shares of common stock to a new employee. The stock options have a four-year vesting schedule, with 25% of the shares vesting after one year and the remaining shares vesting monthly over the subsequent 36 months. This vesting is contingent on the employee's continued service with Syndax.
Syndax Pharmaceuticals (Nasdaq: SNDX), un'azienda biofarmaceutica in fase commerciale focalizzata nello sviluppo di terapie oncologiche innovative, ha annunciato l'assegnazione di un premio di incentivazione secondo il suo Piano di Incentivazione 2023. Il 1° settembre 2024, l'azienda ha concesso opzioni su azioni per acquistare fino a 60.000 azioni di azioni ordinarie a un nuovo dipendente. Le opzioni su azioni hanno un programma di maturazione di quattro anni, con il 25% delle azioni che maturano dopo un anno e le rimanenti azioni che maturano mensilmente nei successivi 36 mesi. Questa maturazione è subordinata alla continuazione del servizio dell'impiegato con Syndax.
Syndax Pharmaceuticals (Nasdaq: SNDX), una empresa biofarmacéutica en etapa comercial centrada en el desarrollo de terapias innovadoras contra el cáncer, ha anunciado la concesión de un premio de incentivo bajo su Plan de Incentivo 2023. El 1 de septiembre de 2024, la compañía otorgó opciones sobre acciones para comprar hasta 60,000 acciones ordinarias a un nuevo empleado. Las opciones sobre acciones tienen un programa de adquisición de cuatro años, con el 25% de las acciones adquiriendo derechos después de un año y las acciones restantes adquiriendo derechos mensualmente durante los 36 meses subsiguientes. Esta adquisición está condicionada a la continuación del servicio del empleado con Syndax.
신닥스 제약(Syndax Pharmaceuticals, Nasdaq: SNDX)은 혁신적인 암 치료법 개발에 집중하는 상업 단계의 생명공학 회사로, 2023년 유인 계획에 따른 유인 상을 수여했다고 발표했습니다. 2024년 9월 1일, 이 회사는 신규 직원에게 최대 60,000주의 보통주를 매입할 수 있는 주식 옵션을 부여했습니다. 이 주식 옵션은 4년의 가속 일정을 가지고 있으며, 1년 후 25%의 주식이 가속되고 나머지 주식은 이후 36개월 동안 월별로 가속됩니다. 이 가속은 신닥스와의 고용 상태가 유지되는 것에 달려 있습니다.
Syndax Pharmaceuticals (Nasdaq: SNDX), une entreprise biopharmaceutique en phase commerciale axée sur le développement de thérapies innovantes contre le cancer, a annoncé l'octroi d'une prime d'incitation dans le cadre de son Plan d'incitation 2023. Le 1er septembre 2024, l'entreprise a accordé des options d'achat d'actions pour acheter jusqu'à 60 000 actions ordinaires à un nouvel employé. Les options d'achat d'actions ont un calendrier d'acquisition de quatre ans, dont 25 % des actions sont acquises après un an, et les actions restantes sont acquises mensuellement au cours des 36 mois suivants. Cette acquisition dépend du maintien du service de l'employé chez Syndax.
Syndax Pharmaceuticals (Nasdaq: SNDX), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf die Entwicklung innovativer Krebstherapien konzentriert, hat die Gewährung einer Incentive-Prämie im Rahmen seines Incentive-Plans 2023 bekannt gegeben. Am 1. September 2024 gewährte das Unternehmen einem neuen Mitarbeiter Optionen zum Erwerb von bis zu 60.000 Aktien von Stammaktien. Die Aktienoptionen haben einen Vesting-Zeitplan von vier Jahren, bei dem 25 % der Aktien nach einem Jahr und die verbleibenden Aktien monatlich über die folgenden 36 Monate vesten. Diese Vesting-Bedingung hängt von der Fortsetzung der Beschäftigung des Mitarbeiters bei Syndax ab.
- Syndax is attracting new talent with stock-based compensation
- The company has a structured employee retention plan through long-term vesting schedules
- None.
About Syndax
Syndax Pharmaceuticals is a commercial stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective menin inhibitor, and Niktimvo™ (axatilimab-csfr), a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment for both revumenib and Niktimvo. For more information, please visit www.syndax.com/ or follow the Company on X (formerly Twitter) and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
View original content:https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302240820.html
SOURCE Syndax Pharmaceuticals, Inc.
FAQ
What inducement grant did Syndax Pharmaceuticals (SNDX) announce on September 6, 2024?
What is the vesting schedule for the stock options granted by Syndax Pharmaceuticals (SNDX)?
When did Syndax Pharmaceuticals (SNDX) grant the inducement award mentioned in the press release?
What is the purpose of Syndax Pharmaceuticals' (SNDX) 2023 Inducement Plan?
